Base de datos : MEDLINE
Búsqueda : sida or vih [Palabras]
Referencias encontradas : 293048 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 29305 va a la página                         

  1 / 293048 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26814962
[Au] Autor:Lorenzo-Redondo R; Fryer HR; Bedford T; Kim EY; Archer J; Kosakovsky Pond SL; Chung YS; Penugonda S; Chipman JG; Fletcher CV; Schacker TW; Malim MH; Rambaut A; Haase AT; McLean AR; Wolinsky SM
[Ad] Dirección:Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60011, USA....
[Ti] Título:Persistent HIV-1 replication maintains the tissue reservoir during therapy.
[So] Fuente:Nature;530(7588):51-6, 2016 Feb 4.
[Is] ISSN:1476-4687
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Lymphoid tissue is a key reservoir established by HIV-1 during acute infection. It is a site associated with viral production, storage of viral particles in immune complexes, and viral persistence. Although combinations of antiretroviral drugs usually suppress viral replication and reduce viral RNA to undetectable levels in blood, it is unclear whether treatment fully suppresses viral replication in lymphoid tissue reservoirs. Here we show that virus evolution and trafficking between tissue compartments continues in patients with undetectable levels of virus in their bloodstream. We present a spatial and dynamic model of persistent viral replication and spread that indicates why the development of drug resistance is not a foregone conclusion under conditions in which drug concentrations are insufficient to completely block virus replication. These data provide new insights into the evolutionary and infection dynamics of the virus population within the host, revealing that HIV-1 can continue to replicate and replenish the viral reservoir despite potent antiretroviral therapy.
[Mh] Términos MeSH primario: Portador Sano/quimioterapia
Portador Sano/virología
Infecciones por VIH/quimioterapia
Infecciones por VIH/virología
VIH-1/crecimiento & desarrollo
Carga Viral
Replicación Viral
[Mh] Términos MeSH secundario: Fármacos Anti-VIH/administración & dosificación
Fármacos Anti-VIH/farmacología
Fármacos Anti-VIH/uso terapéutico
Portador Sano/sangre
Farmacorresistencia Viral/efectos de drogas
Infecciones por VIH/sangre
VIH-1/efectos de drogas
VIH-1/genética
VIH-1/aislamiento & purificación
Haplotipos/efectos de drogas
Humanos
Ganglios Linfáticos/efectos de drogas
Ganglios Linfáticos/virología
Modelos Biológicos
Datos de Secuencia Molecular
Filogenia
Selección Genética/efectos de drogas
Análisis de Secuencia de ADN
Análisis Espacio-Temporal
Factores de Tiempo
Carga Viral/efectos de drogas
Replicación Viral/efectos de drogas
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Anti-HIV Agents)
[Em] Mes de ingreso:1602
[Cu] Fecha actualización por clase:160514
[Lr] Fecha última revisión:160514
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:160204
[St] Status:MEDLINE
[do] DOI:10.1038/nature16933


  2 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26168252
[Au] Autor:Cory TJ; Winchester LC; Robbins BL; Fletcher CV
[Ad] Dirección:Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA....
[Ti] Título:A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.
[So] Fuente:Bioanalysis;7(12):1447-55, 2015.
[Is] ISSN:1757-6199
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Determination of cell-associated antiretroviral drug concentrations is necessary for research into reservoirs of HIV. Variation exists in cell-associated drug concentrations among research groups. One cause for this may be washing cells during processing. We explored spinning cells through oil to minimize this variability. METHODS & RESULTS: Raltegravir, atazanavir, darunavir, efavirenz, lopinavir and ritonavir concentrations were assessed in CEM.ss T cells washed with HBSS and oil-spun cells. Oil-spun cells had significantly higher concentrations for all drugs compared with samples washed with HBSS. CONCLUSION: The decline in cell-associated drug concentrations with saline washes compared with a single spin through oil shows the utility of a spin through oil. Oil centrifugation results in high cell-associated drug concentrations, and can be done in a fast, efficient manner.
[Mh] Términos MeSH primario: Antirretrovirales/química
Aceites/química
[Mh] Términos MeSH secundario: Antirretrovirales/análisis
Línea Celular
Cromatografía Líquida de Alta Presión
Inhibidores de la Proteasa del VIH/análisis
Inhibidores de la Proteasa del VIH/química
Humanos
Soluciones Isotónicas/química
Marcaje Isotópico
Espectrometría de Masas
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nombre de substancia:
0 (Anti-Retroviral Agents); 0 (HIV Protease Inhibitors); 0 (Hanks Balanced Salt Solution); 0 (Isotonic Solutions); 0 (Oils)
[Em] Mes de ingreso:1604
[Cu] Fecha actualización por clase:160514
[Lr] Fecha última revisión:160514
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150714
[St] Status:MEDLINE
[do] DOI:10.4155/bio.15.70


  3 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25690839
[Au] Autor:Li WX; Xia JA; Ma Y; Peng JS; Lu HX
[Ad] Dirección:HLA Typing Laboratory, Blood Center of Wuhan, Wuhan, China.
[Ti] Título:A novel HLA-A allele, HLA-A*02:488, identified by sequence-based typing.
[So] Fuente:Tissue Antigens;85(4):288-9, 2015 Apr.
[Is] ISSN:1399-0039
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:HLA-A*02:488 differs from HLA-A*02:01:01:01 by one nucleotide exchange at position 425(A > G) with an amino exchange.
[Mh] Términos MeSH primario: Alelos
Exones
Infecciones por VIH/genética
Antígeno HLA-A2/genética
Mutación Puntual
[Mh] Términos MeSH secundario: Sustitución de Aminoácidos
Enfermedades Asintomáticas
Secuencia de Bases
Genotipo
Infecciones por VIH/inmunología
Infecciones por VIH/virología
Antígeno HLA-A2/inmunología
Prueba de Histocompatibilidad
Humanos
Masculino
Mediana Edad
Datos de Secuencia Molecular
Reacción en Cadena de la Polimerasa
Alineación de Secuencia
Análisis de Secuencia de ADN
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (HLA-A*02 antigen); 0 (HLA-A2 Antigen)
[Em] Mes de ingreso:1605
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150319
[St] Status:MEDLINE
[do] DOI:10.1111/tan.12531


  4 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25520449
[Au] Autor:Prach LM; Puren A; Lippman SA; Carmona S; Stephenson S; Cutler E; Barnhart S; Liegler T
[Ad] Dirección:University of California San Francisco, San Francisco, California, USA....
[Ti] Título:Design and implementation of an external quality assessment program for HIV viral load measurements using dried blood spots.
[So] Fuente:J Clin Microbiol;53(3):964-6, 2015 Mar.
[Is] ISSN:1098-660X
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:An external quality assurance program was developed for HIV-1 RNA viral load measurements taken from dried blood spots using a reference panel and field-collected specimens. The program demonstrated that accurate and reproducible quantitation can be obtained from field-collected specimens. Residual proviral DNA may confound interpretation in virologically suppressed subjects.
[Mh] Términos MeSH primario: Sangre/virología
Infecciones por VIH/diagnóstico
Infecciones por VIH/virología
VIH-1/aislamiento & purificación
Ensayos de Aptitud de Laboratorios/métodos
Garantía de la Calidad de Atención de Salud/métodos
Carga Viral/normas
[Mh] Términos MeSH secundario: Humanos
ARN Viral/sangre
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nombre de substancia:
0 (RNA, Viral)
[Em] Mes de ingreso:1605
[Cu] Fecha actualización por clase:150902
[Lr] Fecha última revisión:150902
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150221
[St] Status:MEDLINE
[do] DOI:10.1128/JCM.02698-14


  5 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25395030
[Au] Autor:García-Basteiro AL; López-Varela E; Respeito D; González R; Naniche D; Manhiça I; Macete E; Cobelens F; Alonso PL
[Ad] Dirección:Manhiça Health Research Center (CISM), Maputo, Mozambique ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain alberto.garcia-basteiro@manhica.net....
[Ti] Título:High tuberculosis burden among people living with HIV in southern Mozambique.
[So] Fuente:Eur Respir J;45(2):547-9, 2015 Feb.
[Is] ISSN:1399-3003
[Cp] País de publicación:England
[La] Idioma:eng
[Mh] Términos MeSH primario: Infecciones por VIH/complicaciones
Tuberculosis/complicaciones
[Mh] Términos MeSH secundario: Adolescente
Adulto
Femenino
Infecciones por VIH/epidemiología
Humanos
Inmunosupresión
Incidencia
Masculino
Mediana Edad
Mozambique/epidemiología
Salud Pública
Servicios de Salud Rural
Población Rural
Esputo/metabolismo
Tuberculosis/epidemiología
Adulto Joven
[Pt] Tipo de publicación:LETTER
[Em] Mes de ingreso:1605
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150205
[St] Status:MEDLINE
[do] DOI:10.1183/09031936.00145714


  6 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25359338
[Au] Autor:Qin ZZ; Pai M; Van Gemert W; Sahu S; Ghiasi M; Creswell J
[Ad] Dirección:McGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, Canada....
[Ti] Título:How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
[So] Fuente:Eur Respir J;45(2):549-54, 2015 Feb.
[Is] ISSN:1399-3003
[Cp] País de publicación:England
[La] Idioma:eng
[Mh] Términos MeSH primario: Técnicas de Diagnóstico Molecular/métodos
Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico
Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
Tuberculosis Pulmonar/diagnóstico
Tuberculosis Pulmonar/epidemiología
[Mh] Términos MeSH secundario: Algoritmos
Infecciones por VIH/complicaciones
Infecciones por VIH/diagnóstico
Política de Salud
Humanos
Ácidos Nucleicos/análisis
Pruebas en el Punto de Atención
Guías de Práctica Clínica como Asunto
Valor Predictivo de las Pruebas
Juego de Reactivos para Diagnóstico
Sudáfrica
Encuestas y Cuestionarios
Tuberculosis Resistente a Múltiples Medicamentos/complicaciones
Tuberculosis Pulmonar/complicaciones
Organización Mundial de la Salud
[Pt] Tipo de publicación:LETTER
[Nm] Nombre de substancia:
0 (Nucleic Acids); 0 (Reagent Kits, Diagnostic)
[Em] Mes de ingreso:1605
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:150205
[St] Status:MEDLINE
[do] DOI:10.1183/09031936.00147714


  7 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25367908
[Au] Autor:Yoshinaga T; Kobayashi M; Seki T; Miki S; Wakasa-Morimoto C; Suyama-Kagitani A; Kawauchi-Miki S; Taishi T; Kawasuji T; Johns BA; Underwood MR; Garvey EP; Sato A; Fujiwara T
[Ad] Dirección:Discovery Research Laboratory for Core Therapeutic Area, Shionogi & Co., Ltd., Osaka, Japan tomokazu.yoshinaga@shionogi.co.jp....
[Ti] Título:Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
[So] Fuente:Antimicrob Agents Chemother;59(1):397-406, 2015 Jan.
[Is] ISSN:1098-6596
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:GSK1265744 is a new HIV integrase strand transfer inhibitor (INSTI) engineered to deliver efficient antiviral activity with a once-daily, low-milligram dose that does not require a pharmacokinetic booster. The in vitro antiviral profile and mechanism of action of GSK1265744 were established through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clones resistant to other classes of anti-HIV-1 agents and earlier INSTIs. GSK1265744 inhibited HIV replication with low or subnanomolar efficacy and with a selectivity index of at least 22,000 under the same culture conditions. The protein-adjusted half-maximal inhibitory concentration (PA-EC50) extrapolated to 100% human serum was 102 nM. When the virus was passaged in the presence of GSK1265744, highly resistant mutants with more than a 10-fold change (FC) in EC50 relative to that of the wild-type were not observed for up to 112 days of culture. GSK1265744 demonstrated activity against SDM clones containing the raltegravir (RAL)-resistant Y143R, Q148K, N155H, and G140S/Q148H signature variants (FC less than 6.1), while these mutants had a high FC in the EC50 for RAL (11 to >130). Either additive or synergistic effects were observed when GSK1265744 was tested in combination with representative anti-HIV agents, and no antagonistic effects were seen. These findings demonstrate that, similar to dolutegravir, GSK1265744 is differentiated as a new INSTI, having a markedly distinct resistance profile compared with earlier INSTIs, RAL, and elvitegravir (EVG). The collective data set supports further clinical development of GSK1265744.
[Mh] Términos MeSH primario: Fármacos Anti-VIH/uso terapéutico
Infecciones por VIH/quimioterapia
Inhibidores de Integrasa VIH/uso terapéutico
VIH-1/efectos de drogas
Piridonas/uso terapéutico
[Mh] Términos MeSH secundario: Línea Celular
Farmacorresistencia Viral/genética
Infecciones por VIH/virología
Integrasa de VIH/efectos de drogas
VIH-1/genética
Compuestos Heterocíclicos con 3 Anillos/uso terapéutico
Humanos
Pruebas de Sensibilidad Microbiana
Quinolonas/uso terapéutico
Raltegravir Potásico/uso terapéutico
Replicación Viral/efectos de drogas
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Anti-HIV Agents); 0 (GSK1265744); 0 (HIV Integrase Inhibitors); 0 (Heterocyclic Compounds, 3-Ring); 0 (JTK 303); 0 (Pyridones); 0 (Quinolones); 43Y000U234 (Raltegravir Potassium); DKO1W9H7M1 (dolutegravir); EC 2.7.7.- (HIV Integrase)
[Em] Mes de ingreso:1605
[Cu] Fecha actualización por clase:150701
[Lr] Fecha última revisión:150701
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:141224
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.03909-14


  8 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25348535
[Au] Autor:Cutillas V; Mesplede T; Anstett K; Hassounah S; Wainberg MA
[Ad] Dirección:McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada....
[Ti] Título:The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.
[So] Fuente:Antimicrob Agents Chemother;59(1):310-6, 2015 Jan.
[Is] ISSN:1098-6596
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Clinical studies have shown that integrase strand transfer inhibitors (INSTIs) can be used effectively against HIV-1 infection. To date, no resistance substitution has been found in INSTI-naive patients treated with the new integrase inhibitor dolutegravir (DTG). In a recent selection study with DTG, using a virus bearing the H51Y substitution in integrase, the emergence of an R to K substitution at position 262 (R262K) was observed. We characterized this double mutant with respect to integrase strand transfer activity and susceptibility to DTG both biochemically and in tissue culture. We showed that the addition of R262K to H51Y decreased recombinant integrase strand transfer activity but improved integrase DNA-binding affinity, compared to wild-type or H51Y-containing enzymes. The defect in strand transfer activity did not translate into a decrease in HIV-1 infectivity. The combination of H51Y and R262K substitutions slightly decreased susceptibility to DTG (fold change = 1.87) in cell-based resistance assays. Although viral replication was not affected and enzyme efficiency was impaired by the addition of R262K to H51Y, there was an overall increase in the level of biochemical drug resistance against DTG. Our findings suggest that the R at position 262 plays an important role in DNA binding.
[Mh] Términos MeSH primario: Farmacorresistencia Viral/efectos de drogas
Inhibidores de Integrasa VIH/farmacología
Integrasa de VIH/genética
Compuestos Heterocíclicos con 3 Anillos/farmacología
[Mh] Términos MeSH secundario: Sustitución de Aminoácidos
Sitios de Unión
Simulación por Computador
ADN Viral/metabolismo
Células HEK293/efectos de drogas
Células HEK293/virología
Integrasa de VIH/metabolismo
Inhibidores de Integrasa VIH/química
Humanos
Modelos Moleculares
Conformación Proteica
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (DNA, Viral); 0 (HIV Integrase Inhibitors); 0 (Heterocyclic Compounds, 3-Ring); 0 (p31 integrase protein, Human immunodeficiency virus 1); DKO1W9H7M1 (dolutegravir); EC 2.7.7.- (HIV Integrase)
[Em] Mes de ingreso:1605
[Cu] Fecha actualización por clase:150701
[Lr] Fecha última revisión:150701
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:141224
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.04274-14


  9 / 293048 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:25331707
[Au] Autor:Arnold LH; Kunzelmann S; Webb MR; Taylor IA
[Ad] Dirección:Division of Molecular Structure, MRC National Institute for Medical Research, London, United Kingdom....
[Ti] Título:A continuous enzyme-coupled assay for triphosphohydrolase activity of HIV-1 restriction factor SAMHD1.
[So] Fuente:Antimicrob Agents Chemother;59(1):186-92, 2015 Jan.
[Is] ISSN:1098-6596
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:The development of deoxynucleoside triphosphate (dNTP)-based drugs requires a quantitative understanding of any inhibition, activation, or hydrolysis by off-target cellular enzymes. SAMHD1 is a regulatory dNTP-triphosphohydrolase that inhibits HIV-1 replication in human myeloid cells. We describe here an enzyme-coupled assay for quantifying the activation, inhibition, and hydrolysis of dNTPs, nucleotide analogues, and nucleotide analogue inhibitors by triphosphohydrolase enzymes. The assay facilitates mechanistic studies of triphosphohydrolase enzymes and the quantification of off-target effects of nucleotide-based antiviral and chemotherapeutic agents.
[Mh] Términos MeSH primario: Ácido Anhídrido Hidrolasas/análisis
Bioensayo/métodos
Evaluación Preclínica de Medicamentos/métodos
Proteínas de Unión al GTP Monoméricas/análisis
Proteínas de Unión al GTP Monoméricas/metabolismo
[Mh] Términos MeSH secundario: Ácido Anhídrido Hidrolasas/genética
Ácido Anhídrido Hidrolasas/metabolismo
Aciclovir/química
Aciclovir/metabolismo
Aciclovir/farmacología
Nucleótidos de Adenina/química
Nucleótidos de Adenina/farmacología
Antivirales/química
Antivirales/metabolismo
Antivirales/farmacología
Arabinonucleósidos/química
Arabinonucleósidos/farmacología
Catálisis/efectos de drogas
Desoxirribonucleótidos/química
Desoxirribonucleótidos/metabolismo
Relación Dosis-Respuesta a Droga
Ganciclovir/química
Ganciclovir/farmacología
VIH-1
Hidrólisis
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Adenine Nucleotides); 0 (Antiviral Agents); 0 (Arabinonucleosides); 0 (Deoxyribonucleotides); 762RDY0Y2H (clofarabine); EC 3.6.- (Acid Anhydride Hydrolases); EC 3.6.1.- (SAMHD1 protein, human); EC 3.6.1.11 (exopolyphosphatase); EC 3.6.5.2 (Monomeric GTP-Binding Proteins); P9G3CKZ4P5 (Ganciclovir); X4HES1O11F (Acyclovir)
[Em] Mes de ingreso:1605
[Cu] Fecha actualización por clase:150116
[Lr] Fecha última revisión:150116
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:141224
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.03903-14


  10 / 293048 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25483501
[Au] Autor:Garrod T; Grubor-Bauk B; Yu S; Gargett T; Gowans EJ
[Ad] Dirección:a Discipline of Surgery ; the University of Adelaide; Basil Hetzel Institute ; Adelaide , SA Australia.
[Ti] Título:Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.
[So] Fuente:Hum Vaccin Immunother;10(9):2679-83, 2014.
[Is] ISSN:2164-554X
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:In humans, DNA vaccines have failed to demonstrate the equivalent levels of immunogenicity that were shown in smaller animals. Previous studies have encoded adjuvants, predominantly cytokines, within these vaccines in an attempt to increase antigen-specific immune responses. However, these strategies have lacked breadth of innate immune activation and have led to disappointing results in clinical trials. Damage associated molecular patterns (DAMPs) have been identified as pattern recognition receptor (PRR) agonists. DAMPs can bind to a wide range of PRRs on dendritic cells (DCs) and thus our studies have aimed to utilize this characteristic to act as an adjuvant in a DNA vaccine approach. Specifically, HSP70 has been identified as a DAMP, but has been limited by its lack of accessibility to PRRs in and on DCs. Here, we discuss the promising results achieved with the inclusion of membrane-bound or secreted HSP70 into a DNA vaccine encoding HIV gag as the model immunogen.
[Mh] Términos MeSH primario: Vacunas contra el SIDA/inmunología
Adyuvantes Inmunológicos/metabolismo
Proteínas HSP70 de Choque Térmico/metabolismo
Perforina/metabolismo
Vacunas de ADN/inmunología
[Mh] Términos MeSH secundario: Vacunas contra el SIDA/administración & dosificación
Vacunas contra el SIDA/genética
Adyuvantes Inmunológicos/genética
Animales
Proteínas HSP70 de Choque Térmico/genética
Perforina/genética
Vacunas de ADN/administración & dosificación
Vacunas de ADN/genética
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nombre de substancia:
0 (AIDS Vaccines); 0 (Adjuvants, Immunologic); 0 (HSP70 Heat-Shock Proteins); 0 (Vaccines, DNA); 126465-35-8 (Perforin)
[Em] Mes de ingreso:1605
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:141222
[St] Status:MEDLINE
[do] DOI:10.4161/hv.29527



página 1 de 29305 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud